Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868822 | 0.84 | KDM4E (1.00) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL2706918 | 0.81 | KDM4E (0.77) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL3850930 | 0.81 | KDM4E (0.75) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL8067617 | 0.77 | KDM4E (0.69) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL27931675 | 0.77 | KDM4E (0.69) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL7811485 | 0.76 | KDM4E (0.67) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL28471797 | 0.73 | KDM4E (0.64) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL3482945 | 0.73 | KDM4E (0.62) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL17760582 | 0.73 | KDM4E (0.62) | KDM4EKMT2AALDH1A1TSHRMEN1 | |
| SCHEMBL1420044 | 0.72 | KDM4E (0.61) | KDM4EKMT2AALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060292202-A1 | Drug delivery device | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | claimed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110135611-A1 | METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060292202-A1 | Drug delivery device | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | disclosed |
| CN-1813723-A | Application of gaba-receptor modulators for the preventing/or treatment of neurodegenerative diseases of the eye | MANN GERHARD CHEM PHARM FAB (DE) | 2006-08-09 | — | — | CN | disclosed |
| US-20040102438-A1 | Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye | DR. GERHARD MANN CHEM.-PHARM. FABRIK GMGH (DE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | KDM4E 2095/4885KMT2A 1331/4885ALDH1A1 2164/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | KDM4E 3176/4885KMT2A 2546/4885ALDH1A1 1581/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | KDM4E 1039/4885KMT2A 257/4885ALDH1A1 1837/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | KDM4E 2169/4885KMT2A 2037/4885ALDH1A1 1807/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | KDM4E 2527/4885KMT2A 1893/4885ALDH1A1 1565/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | KDM4E 2859/4885KMT2A 1997/4885ALDH1A1 3011/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | KDM4E 2095/4885KMT2A 1331/4885ALDH1A1 2164/4885 |
| US-20060292202-A1 | Drug delivery device | ALDH1A2, ADRB2, ADRA2B | KDM4E 3594/4885KMT2A 3112/4885ALDH1A1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.